Literature DB >> 9705825

Post-translational modification of transthyretin in plasma.

H Terazaki1, Y Ando, O Suhr, P I Ohlsson, K Obayashi, T Yamashita, S Yoshimatsu, M Suga, M Uchino, M Ando.   

Abstract

To determine the behavior of transthyretin (TTR) in blood circulation, TTR purified from normal subjects' plasma was injected to rats, and blood and urine were collected time dependently. Although TTR in plasma was proven to be a predominantly cysteine (Cys) conjugated form by electrospray ionization mass spectrometry (ESI-MS) analysis, it was gradually converted into free, 32 Da (dihydroxylation), 80 Da (phosphorylation), and 306 Da (glutathionylation), increased forms in molecular weight of TTR. The plasma levels of TTR were decreased in a time-dependent manner with the half life of 72.4 min. No secretion of TTR into the urine was observed by ESI-MS. In conclusion, this method can be simply performed without loading a radioactive molecule to the targeted protein. It offers a possibility to determine natural protein behaviors in the blood stream.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9705825     DOI: 10.1006/bbrc.1998.9097

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma.

Authors:  H E Purkey; M I Dorrell; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

2.  Decreased clearance of serum retinol-binding protein and elevated levels of transthyretin in insulin-resistant ob/ob mice.

Authors:  Nimesh Mody; Timothy E Graham; Yuki Tsuji; Qin Yang; Barbara B Kahn
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-02-19       Impact factor: 4.310

3.  Alteration of transthyretin microheterogeneity in serum of multiple trauma patients.

Authors:  Beate Gericke; Jens Raila; Maria Deja; Sascha Rohn; Bernd Donaubauer; Britta Nagl; Sophie Haebel; Florian J Schweigert; Udo Kaisers
Journal:  Biomark Insights       Date:  2007-08-08

4.  Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients.

Authors:  Beate Gericke; Jens Raila; Jalid Sehouli; Sophie Haebel; Dominique Könsgen; Alexander Mustea; Florian J Schweigert
Journal:  BMC Cancer       Date:  2005-10-17       Impact factor: 4.430

5.  Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.

Authors:  John F Timms; Elif Arslan-Low; Musarat Kabir; Jenny Worthington; Stephane Camuzeaux; John Sinclair; Joanna Szaub; Babak Afrough; Vladimir N Podust; Evangelia-Ourania Fourkala; Myriam Cubizolles; Florian Kronenberg; Eric T Fung; Aleksandra Gentry-Maharaj; Usha Menon; Ian Jacobs
Journal:  Proteomics Clin Appl       Date:  2014-11-10       Impact factor: 3.494

6.  The Extracellular Protein, Transthyretin Is an Oxidative Stress Biomarker.

Authors:  Meesha Sharma; Sheeza Khan; Safikur Rahman; Laishram Rajendrakumar Singh
Journal:  Front Physiol       Date:  2019-01-24       Impact factor: 4.566

7.  Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay.

Authors:  Florian J Schweigert; Kerstin Wirth; Jens Raila
Journal:  Proteome Sci       Date:  2004-09-01       Impact factor: 2.480

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.